PA
LUCD icon

Parallel Advisors’s Lucid Diagnostics LUCD Stock Holding History

Parallel Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,000
Closed -$46K – 3632
2025
Q2 		$46K Buy
+40,000
New +$51.7K ﹤0.01% 1771

Other funds holding LUCD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Parallel Advisors's LUCD Position: Q3 2025 in Review

Parallel Advisors sold out of Lucid Diagnostics (LUCD) in Q3 2025, closing a stake of 40,000 shares — an estimated $46K sold.

Parallel Advisors first reported a position in LUCD in Q2 2025 and held it in 1 quarter. The position peaked at $46K in Q2 2025. 86 funds tracked by Wall St. Rank hold LUCD as of Q3 2025.

  • Parallel Advisors reported no remaining Lucid Diagnostics position as of Q3 2025 after selling out during the quarter.
  • Parallel Advisors sold 40,000 Lucid Diagnostics shares in Q3 2025, an estimated $46K.
  • Parallel Advisors first reported a position in Lucid Diagnostics in Q2 2025 and held it in 1 quarter.
  • Parallel Advisors's Lucid Diagnostics position peaked at $46K in Q2 2025.
  • 86 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2025.

Based on Parallel Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.